Should we increase GFR with bardoxolone in Alport syndrome?
Bardoxolone methyl is a semisynthetic oleanane triterpenoid, and it is thought to act by promoting the resolution of inflammation via activation of Nrf-2 and inhibition of NF k–light-chain enhancer of activated B cells. Initial phase 1 studies showed, as an incidental finding, that bardoxolone incre...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Published: |
American Society of Nephrology
2018
|